Answer
Chronic intravenous human immunoglobulin (IVIg) treatment may decrease serum ravulizumab concentrations by interfering with the endosomal neonatal Fc receptor (FcRn) recycling mechanism of monoclonal antibodies.
Sources for this answer
- Ultomiris 300 mg/3 mL and 1100 mg/11 mL PLGB 31187/0007Alexion Pharma UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 11Document updated
Sources checked